STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report first quarter 2024 financial results on May 14, 2024, after the U.S. financial markets close. The company will also provide a business update and host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation material on the company's website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.

A live webcast of the call and the presentation material will be available on the “Events” section of the Company’s website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.

About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including two FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit http://www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.

Contacts:

Media
Amanda Sheldon, Head of Corporate Communications
asheldon@arcutis.com

Investors
Latha Vairavan, Vice President, Finance and Investor Relations
lvairavan@arcutis.com

Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com


FAQ

When will Arcutis Biotherapeutics report first quarter 2024 financial results?

Arcutis Biotherapeutics will report first quarter 2024 financial results on May 14, 2024, after the U.S. financial markets close.

What time will the conference call and webcast be held on May 14, 2024?

The conference call and webcast will be held at 4:30 p.m. ET on May 14, 2024.

Where can investors access the live webcast and presentation material?

Investors can access the live webcast and presentation material on the 'Events' section of Arcutis Biotherapeutics' website.

Will there be an archived replay of the webcast available?

Yes, an archived replay of the webcast will be available on the Arcutis investor website following the conference call.
Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

ARQT Rankings

ARQT Latest News

ARQT Latest SEC Filings

ARQT Stock Data

3.72B
110.42M
1.9%
109.89%
14.19%
Biotechnology
Pharmaceutical Preparations
Link
United States
WESTLAKE VILLAGE